Liraglutide vs Semaglutide Compared
Liraglutide
-15.8% body weight
In the only head-to-head trial (STEP 8), semaglutide 2.4 mg weekly produced 15.8% weight loss vs 6.4% for liraglutide 3.0 mg daily over 68 weeks in 338 adults with obesity.
Rubino et al., JAMA, 2022
Rubino et al., JAMA, 2022
View as imageLiraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists approved for weight management, both made by Novo Nordisk, and both derived from the same parent molecule. Yet semaglutide has largely replaced liraglutide in clinical practice. The reason is straightforward: in the only head-to-head randomized trial, semaglutide produced 2.5 times more weight loss with once-weekly dosing instead of daily injections. This article breaks down exactly how the two drugs differ, what the clinical data show, and where liraglutide still has a role. For background on the liraglutide pediatric evidence or a broader GLP-1 class overview, see the cluster pillar article.
Key Takeaways
- STEP 8 (n=338): semaglutide 2.4 mg weekly produced 15.8% body weight loss vs 6.4% for liraglutide 3.0 mg daily at 68 weeks (difference: -9.4 percentage points, P<0.001) (Rubino et al., 2022)
- 55.6% of semaglutide patients lost 15% or more body weight vs 12.0% for liraglutide; 38.5% vs 6.0% achieved 20% or more loss (Rubino et al., 2022)
- Treatment discontinuation was lower with semaglutide (13.5%) than liraglutide (27.6%), despite similar GI adverse event rates (~83-84%)
- The molecular difference: semaglutide uses a C18 fatty diacid (vs C16 for liraglutide) producing 5.6x higher albumin affinity and 165-hour half-life vs 13 hours (Knudsen & Lau, 2019)
- Converting from liraglutide to semaglutide reduced HbA1c by 0.5% and saved over $400,000 at a single VA Medical Center (Hardin et al., 2023)
- Both drugs reduce major cardiovascular events in patients with diabetes and established CVD (Verma et al., 2022)
The STEP 8 Trial: The Only Head-to-Head Data
Before STEP 8, comparisons between liraglutide and semaglutide relied on cross-trial analysis, a method plagued by differences in patient populations, trial design, and endpoints. STEP 8 solved this by directly randomizing patients to one drug or the other in the same trial.[1]
Study Design
- Population: 338 adults with BMI 30 or greater (or 27+ with comorbidities), without diabetes
- Randomization: 3:1:3:1 to semaglutide 2.4 mg weekly (n=126), matched placebo, liraglutide 3.0 mg daily (n=127), or matched placebo. Placebo groups pooled (n=85)
- Duration: 68 weeks
- Setting: 19 US sites, September 2019 to May 2021
- Design: Open-label for active drug comparison; double-blinded against matched placebo groups
Weight Loss Results
| Outcome | Semaglutide | Liraglutide | Placebo |
|---|---|---|---|
| Mean weight change | -15.8% | -6.4% | -1.9% |
| Lost 10%+ | 70.9% | 25.6% | 15.3% |
| Lost 15%+ | 55.6% | 12.0% | 6.9% |
| Lost 20%+ | 38.5% | 6.0% | 2.8% |
The difference between semaglutide and liraglutide was -9.4 percentage points (95% CI: -12.0 to -6.8; P<0.001). Semaglutide patients had 6.3x greater odds of achieving 10% weight loss and 8.2x greater odds of achieving 20% weight loss compared to liraglutide.
Tolerability and Discontinuation
Gastrointestinal adverse events occurred at similar rates: 84.1% with semaglutide vs 82.7% with liraglutide. These were predominantly nausea, diarrhea, and constipation, consistent with the GLP-1 drug class. What differed was discontinuation: 13.5% stopped semaglutide vs 27.6% stopped liraglutide.
The lower discontinuation rate with semaglutide is counterintuitive given similar GI side effects. The likely explanation is that patients seeing greater weight loss are more motivated to continue treatment despite side effects. Additionally, the once-weekly injection may impose less psychological burden than daily injections.
Why Semaglutide Works Better: The Chemistry
Both drugs are GLP-1 analogs that activate the same receptor. The efficacy difference traces to pharmacokinetic optimization, not pharmacodynamic differences.[2]
Structural Differences
| Feature | Liraglutide | Semaglutide |
|---|---|---|
| Fatty acid | C16 palmitic acid | C18 octadecanoic diacid |
| Spacer | Gamma-glutamic acid | Gamma-Glu + 2x OEG |
| DPP-4 protection | Arg34 substitution | Aib8 substitution |
| Albumin affinity | Baseline | 5.6x higher |
| Half-life | 13 hours | 165 hours |
| Dosing | Once daily (SC) | Once weekly (SC) |
| Approved obesity dose | 3.0 mg/day | 2.4 mg/week |
The C18 diacid with a longer OEG spacer creates dramatically stronger albumin binding. Combined with the Aib8 substitution that confers near-complete DPP-4 resistance, semaglutide achieves sustained GLP-1 receptor engagement throughout the week. Liraglutide's 13-hour half-life means significant trough periods between daily doses when receptor activation drops. For a deeper dive into lipidated peptide chemistry, see the delivery cluster.
Implications for Appetite Suppression
The sustained receptor engagement matters because GLP-1's appetite-suppressing effect is dose- and exposure-dependent. Semaglutide reduces caloric intake by approximately 35% compared to placebo, while liraglutide reduces it by approximately 16%.[3] Semaglutide has also been associated with greater reductions in food cravings and preference for high-fat foods, effects that are less pronounced with liraglutide. These differences likely reflect the more sustained hypothalamic GLP-1 receptor activation that semaglutide's longer half-life provides.
The Broader STEP Program Context
STEP 8 does not exist in isolation. The STEP trial program established semaglutide's weight loss profile across multiple populations.[3]
- STEP 1 (n=1,961): -14.9% weight loss at 68 weeks vs -2.4% placebo
- STEP 2 (n=1,210, with T2D): -9.6% vs -3.4%
- STEP 3 (n=611, with intensive behavioral therapy): -16.0% vs -5.7%
- STEP 5 (n=304, 2-year data): -15.2% vs -2.6%, sustained at 104 weeks
The consistency of 14-16% weight loss across different populations and trial designs strengthens confidence that STEP 8's superiority over liraglutide reflects a real drug effect rather than trial-specific bias.
Weight Regain After Stopping
The STEP 1 extension showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of lost weight within one year.[4] Cardiometabolic improvements (blood pressure, lipids, waist circumference, HbA1c) also reversed partially. This is consistent with obesity as a chronic disease requiring ongoing treatment, analogous to hypertension or diabetes medications.
Liraglutide shows similar weight regain patterns. This is not a differentiator between the two drugs; it is a class effect that applies to all GLP-1 agonists and reflects the biology of energy homeostasis rather than a drug-specific limitation.
Cardiovascular Outcomes
Both drugs have demonstrated cardiovascular benefit in patients with diabetes and established CVD, though in separate trials (LEADER for liraglutide, SUSTAIN-6 and SELECT for semaglutide).
Verma et al. (2022) conducted a post hoc analysis of cardiovascular outcomes specifically in patients with peripheral artery disease (PAD).[5] Both liraglutide and semaglutide reduced major adverse cardiovascular events (MACE) in this high-risk subgroup, with consistent direction of effect. The SELECT trial later demonstrated that semaglutide 2.4 mg reduced MACE by 20% in people with obesity and established CVD regardless of diabetes status, a result liraglutide has not replicated in a non-diabetes population.
Real-World Conversion Data
Hardin et al. (2023) reported outcomes from converting 304 veterans from liraglutide to semaglutide at a VA Medical Center.[6] After conversion (liraglutide 0.6-1.2 mg daily to semaglutide 0.25-0.5 mg weekly), mean HbA1c dropped from 8.1% to 7.6% (P<0.001), body weight decreased, and the institution saved over $400,000 in pharmaceutical costs. Common adverse effects during the transition included hypoglycemia and GI intolerance, but the transition was completed without major complications in most patients.
This real-world data confirms that the clinical superiority seen in STEP 8 translates to practice settings. The cost savings are notable because semaglutide and liraglutide have similar list prices, but the diabetes doses of semaglutide (0.25-1.0 mg weekly) require less drug per month than daily liraglutide.
Where Liraglutide Still Has a Role
Despite semaglutide's superiority in weight loss, liraglutide retains specific clinical niches:
Pediatric/adolescent use. Liraglutide has more established pediatric evidence and was approved for adolescent obesity before semaglutide.
Dose titration sensitivity. Some patients who cannot tolerate semaglutide's escalation to 2.4 mg may do better with liraglutide's more granular daily dose adjustments (0.6 mg increments). The daily dosing allows finer titration around GI tolerability.
Insurance and access. Coverage varies by insurer and indication. In some formularies, liraglutide is preferred or available at lower out-of-pocket cost. For more on this issue, see Is Saxenda Still Worth It?
Long-term safety data. Liraglutide has been on the market longer (since 2010 for diabetes, 2014 for obesity) and has a larger post-marketing safety database. For patients or clinicians prioritizing long-term safety confidence, this history matters.
Generic availability. Liraglutide is closer to patent expiration than semaglutide, which may eventually make it the more economical option in markets where generics become available.
Limitations of the Comparison
STEP 8 was open-label. Participants knew which drug they received. This introduces potential bias in subjective outcomes (food cravings, satisfaction) though body weight is an objective measure.
No diabetes population. STEP 8 enrolled only participants without diabetes. Whether the 2.5x efficacy ratio holds in type 2 diabetes is not established in a head-to-head trial, though cross-trial comparison suggests the difference is smaller in diabetes populations.
68 weeks is not forever. Both drugs require chronic use. Whether semaglutide's advantage persists over 5-10 years, or whether compensatory mechanisms narrow the gap over time, is unknown.
Dose comparison may not be equivalent. Whether semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily represent equivalent biological dosing (accounting for receptor binding kinetics, tissue exposure, and CNS penetration) is debatable. The comparison is at marketed doses, not at receptor-occupancy-equivalent doses.
The Bottom Line
The STEP 8 trial provided definitive head-to-head evidence that semaglutide 2.4 mg weekly produces 2.5 times more weight loss than liraglutide 3.0 mg daily (15.8% vs 6.4% at 68 weeks). The superiority traces to pharmacokinetic optimization: a C18 diacid providing 5.6x higher albumin affinity, 165-hour half-life, and sustained receptor engagement. Both drugs share similar GI side effect profiles and cardiovascular benefits. Liraglutide retains roles in pediatric obesity, dose-sensitive patients, and settings where cost or access favors the older drug.